204
Participants
Start Date
July 3, 2014
Primary Completion Date
May 2, 2019
Study Completion Date
May 3, 2023
Avelumab
Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
Royal North Shore Hospital, St Leonards
Port Macquarie Base Hospital, Port Macquarie
Peter MacCallum Cancer Centre, East Melbourne
Princess Alexandra Hospital, Woolloongabba
St John of God Subiaco Hospital, Perth
Memorial Sloan Kettering Cancer Center, New York
Mount Sinai, New York
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo
Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin
Hôpital de la Timone, Marseille
University of Pittsburgh, Pittsburgh
Fox Chase Cancer Center, Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
IEO Istituto Europeo di Oncologia, Milan
National Cancer Institute, Bethesda
Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Lübeck
Universitaetsklinikum Schleswig-Holstein - Klinik fuer Allgemeine Innere Medizin, Kiel
CHU Besançon - Hôpital Jean Minjoz, Besançon
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario 12 de Octubre, Madrid
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa
IOV - Istituto Oncologico Veneto IRCCS, Padua
Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
CHU Nantes - Hôtel Dieu, Nantes
St. Josef-Hospital Universitaetsklinikum, Bochum
Universitaetsklinikum Essen, Essen
Hospital General Universitario de Valencia, Valencia
Fachklinik Hornheide, Münster
Universitaetsklinikum Koeln, Cologne
A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena
Hopital Claude Huriez - CHU Lille, Lille
Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt am Main
Washington University School of Medicine, St Louis
Universitaetsklinikum Heidelberg, Heidelberg
Centre Hospitalier Lyon Sud, Pierre-Bénite
Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
Hôpital Saint-Louis, Paris
University of Colorado, Aurora
Istituto Nazionale Tumori Fondazione G.Pascale, Napoli
UCLA Medical Center, Los Angeles
The Angeles Clinic and Research Institute - West LA, Los Angeles
Institut Gustave Roussy, Villejuif
University of Washington - Seattle Cancer Care Alliance, Seattle
Helios Klinikum Erfurt, Erfurt
Dana Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
Tasman Oncology Research Ltd, Southport
Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux
Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne-Billancourt
CHU Tours - Hôpital Trousseau, Chambray-lès-Tours
CHU de Dijon - Hopital du Bocage, Dijon
CHU de Grenoble - Hôpital A Michallon, Grenoble
CHU de Limoges - Hôpital Dupuytren, Limoges
National Cancer Center Hospital, Chūōku
CHU Nice - Hopital de l Archet 2, Nice
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia
Istituto Nazionale Tumori Regina Elena IRCCS, Roma
Shizuoka Cancer Center, Shizuoka
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
EMD Serono Research & Development Institute, Inc.
INDUSTRY